Archives
-
Phosphatase Inhibitor Cocktail 2: Assay Guide
2026-09-30
This scenario-based guide explains how Phosphatase Inhibitor Cocktail 2 (100X in ddH2O), SKU K1013, supports protein phosphorylation preservation in lysates from viability, proliferation, and cytotoxicity studies. It covers assay compatibility, 1:100 preparation, storage, interpretation, and practical vendor-selection criteria.
-
EZ Cap™ Cas9 mRNA (m1Ψ) in Viability Assays
2026-09-30
Learn how EZ Cap™ Cas9 mRNA (m1Ψ), SKU R1014, can support better-controlled CRISPR-Cas9 perturbation experiments that feed into viability, proliferation, and cytotoxicity assays. The article connects formulation choices, RNA handling, assay controls, and data interpretation without treating a viability signal as a substitute for editing validation.
-
CCG-1423: RhoA Signaling to Translation
2026-09-29
CCG-1423 offers a pathway-focused way to investigate MRTF-A nuclear import, RhoA-driven transcription, invasion, and apoptosis. This thought-leadership guide connects its oncology research utility with emerging evidence that RhoA/ROCK1/MLC2 signaling remodels tight junctions during Minute Virus of Canines infection, while clearly separating established findings from translational hypotheses.
-
Lambda Protein Phosphatase for BMAL1 Validation
2026-09-29
Lambda Protein Phosphatase (λ-PPase) is a Mn2+-dependent enzyme for broad protein dephosphorylation and phosphorylation site validation. K1102 provides a controlled way to test whether BMAL1 phosphorylation affects antibody recognition, transcriptional activity, or condensate behavior.
-
Methotrexate A4347: Reliable Cell Assays
2026-09-28
This scenario-driven guide shows how Methotrexate (SKU A4347) can be incorporated into cell viability, proliferation, apoptosis, and immunosuppression workflows. It covers mechanism, solvent compatibility, dose–time design, interpretation, and practical vendor-selection criteria using documented product parameters.
-
Recombinant Human FGF-19: Assay Workflow
2026-09-28
Recombinant Human FGF-19 provides a defined protein input for FGFR4 binding, cell-response, and metabolic regulation research, with dossier-reported activity and handling specifications. It is suitable for controlled in vitro research workflows; activity in other cell types, primary systems, or in vivo models requires independent validation.
-
Ibrutinib (PCI-32765): BTK Assay Guide
2026-09-27
A practical guide to using Ibrutinib (PCI-32765), SKU A3001, in B-cell viability and signaling experiments. Covers assay design, compound handling, interpretation limits, and evidence-based supplier selection without confusing biochemical potency with cellular response.
-
Clozapine Workflows for Schizophrenia Research
2026-09-26
Use Clozapine to connect receptor pharmacology with ERK1/2 pathway assays and preclinical models of treatment-resistant schizophrenia. This practical guide separates drug-response experiments from recent magnetic-stimulation findings, with workflow options for signaling, cell viability, and hepatotoxicity studies.
-
Phosbind Acrylamide: From Signal to Evidence
2026-09-25
Phosphorylation is a dynamic regulatory signal, but a single antibody readout rarely tells the whole story. This article connects findings on cyanobacterial Hik33 signaling with practical, antibody-independent SDS-PAGE phosphorylation detection, and outlines where Phosbind Acrylamide can strengthen translational research workflows—and where orthogonal validation remains essential.
-
Ertugliflozin, Brain Insulin Signaling, and Tau
2026-09-25
In a streptozotocin-induced rat model of Alzheimer-like pathology, ertugliflozin attenuated cognitive deficits and several hippocampal abnormalities, including tau hyperphosphorylation. Changes in IRS-1, Akt, and GSK3β phosphorylation are consistent with improved insulin signaling, although the study does not establish that this pathway change caused the behavioral or pathological effects.
-
Peptidisc-Assisted Assembly of Multimeric Nanobodies
2026-09-24
Yilun Chen and Franck Duong van Hoa describe a strategy that couples nanobodies to transmembrane segments and uses peptidiscs to stabilize hydrophobically driven assemblies. The resulting polybodies showed avidity-related benefits in GFP and human serum albumin applications, while bispecific and autofluorescent examples suggest a broader engineering potential.
-
H 89 2HCl: Interpreting PKA Inhibition in Bone
2026-09-24
Learn how H 89 2HCl can help test cAMP/PKA signaling during osteoclast differentiation—and why inhibitor results need dose-aware interpretation. This article connects a dopamine–CREB study to practical controls for distinguishing pathway evidence from compound effects.
-
Lambda Protein Phosphatase for BMAL1 Studies
2026-09-23
Use Lambda Protein Phosphatase to test whether phosphorylation contributes to BMAL1 antibody signals, protein behavior, or condensate formation. A controlled, paired-sample workflow helps distinguish phospho-dependent effects from changes in total protein or assay conditions.
-
Panobinostat and Calcineurin Degradation in Myeloma
2026-09-23
The reference study identifies calcineurin catalytic subunit PPP3CA as a therapeutically relevant vulnerability in multiple myeloma and shows that panobinostat promotes its degradation through disruption of HSP90 chaperone support. The findings connect PPP3CA abundance with advanced disease and possible bortezomib resistance, while supporting combined HDAC and calcineurin inhibition as a mechanistically informed strategy.
-
SIRT6, Nucleolar Remodeling, and Proteostasis
2026-09-22
The reference study identifies SIRT6 as a regulator of proteostasis that restrains ribosomal gene activity, nucleolar expansion, and global protein synthesis. Its findings connect chromatin and nucleolar dysregulation to impaired folding capacity, aggregate formation, and neurodegeneration-associated stress intolerance.